・RIKEN reorganized into Kagaku-Kenkyusho (the first president, Dr. Yoshio Nishina)

・Penicillin production started

・Streptomycin production started

・Kagaku-Kenkyusho renamed Kaken Chemicals

・Kaken Chemicals listed on the First Section of the Tokyo Stock Exchange

・Shizuoka Factory opened

・Shiga Factory opened

・Brufen launched

・Kyoto Research Laboratories completed in Yamashina, Kyoto

・Eustin (Salinomycin) launched

・Kaken Chemicals merged with Kakenyaku-Kako to form KAKEN PHARMACEUTICAL

・Seven E-P launched

・Artz launched

・Empynase-PD launched

・Fiblast in-licensed from California Biotechnology (Scios)

・Adofeed launched

・Komagome redevelopment plan started

・Ebrantil launched

・Head office moved to Urayasu in Chiba

・Mentax launched

・Mentax out-licensed to Penederm, (renamed to Bertek recently)

・Procylin launched

・Ropion launched

・Artz Dispo launched

・Pronase-MS launched

・Uroston launched

・Cytotec launched

・Mentax approved by U.S.　Food and Drug Administration

・Seprafilm marketing agreement made with Genzyme Corp.

・Bunkyo Green Court completed

・50th Anniversary celebrated

・Pentoxazon launched

・Seprafilm launched

・Lipantil launched

・Mr. Inui named for the president

・Shiga Factory closed

・Mirol launched

・Fiblast Spray launched

・ISO14001 obtained in Shizuoka site

・Mentax launched as OTC in U.S.

・Drug Information Service Office opened

・Mentax Spray launched

・Lipidil launched

・bFGF-the rights to develop, manufacture and sell on a world basis obtained

・Licensing Agreement for Antifungal compound “KP-103” in North America and Europe

・Licensing Agreement for Dental Applications of bFGF in North America and Europe

・Licensing Agreement for Anti-alpha-9 integrin antibodies on a world basis

・Berasus lanched

・License Agreement for bFGF in Wound Healing Applications in Europe and North America